IN2012DN01325A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01325A
IN2012DN01325A IN1325DEN2012A IN2012DN01325A IN 2012DN01325 A IN2012DN01325 A IN 2012DN01325A IN 1325DEN2012 A IN1325DEN2012 A IN 1325DEN2012A IN 2012DN01325 A IN2012DN01325 A IN 2012DN01325A
Authority
IN
India
Prior art keywords
alkyl
independently
pi3k
heteroaryl
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Joseph Shuttleworth
Alexander Richard Liam Cecil
Thomas James Hill
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0914594A external-priority patent/GB0914594D0/en
Priority claimed from GBGB1005584.6A external-priority patent/GB201005584D0/en
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of IN2012DN01325A publication Critical patent/IN2012DN01325A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1325DEN2012 2009-08-20 2010-08-19 IN2012DN01325A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0914594A GB0914594D0 (en) 2009-08-20 2009-08-20 Compounds
GBGB1005584.6A GB201005584D0 (en) 2010-04-01 2010-04-01 Compounds
PCT/GB2010/051370 WO2011021038A1 (en) 2009-08-20 2010-08-19 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN01325A true IN2012DN01325A (enExample) 2015-06-05

Family

ID=42756474

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1325DEN2012 IN2012DN01325A (enExample) 2009-08-20 2010-08-19

Country Status (15)

Country Link
US (4) US9200007B2 (enExample)
EP (1) EP2467387B1 (enExample)
JP (1) JP5746172B2 (enExample)
CN (1) CN102498115B (enExample)
AU (1) AU2010286168B2 (enExample)
BR (1) BR112012003955A2 (enExample)
CA (1) CA2771594C (enExample)
ES (1) ES2534326T3 (enExample)
IL (1) IL217903A (enExample)
IN (1) IN2012DN01325A (enExample)
MX (1) MX2012002059A (enExample)
NZ (1) NZ597983A (enExample)
PL (1) PL2467387T3 (enExample)
WO (1) WO2011021038A1 (enExample)
ZA (1) ZA201200910B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771594C (en) 2009-08-20 2018-05-01 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
AU2015268776B2 (en) * 2010-12-16 2017-04-13 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
DK2651951T3 (en) 2010-12-16 2014-12-08 Hoffmann La Roche TRICYCLIC PI3K INHIBITOR COMPOUNDS AND PROCEDURES FOR USE THEREOF
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
WO2014044722A1 (en) 2012-09-20 2014-03-27 Basf Se Azadibenzofurans for electronic applications
MX364295B (es) 2012-11-07 2019-04-22 Karus Therapeutics Ltd Inhibidores de histona desacetilasa novedosos y su uso en terapia.
WO2014072937A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
AR095443A1 (es) * 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
LT2994465T (lt) 2013-05-10 2018-10-10 Karus Therapeutics Limited Nauji histono deacetilazės inhibitoriai
US9814037B2 (en) * 2013-06-28 2017-11-07 Intel Corporation Method for efficient channel estimation and beamforming in FDD system by exploiting uplink-downlink correspondence
CN104557955B (zh) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
AU2016369528B2 (en) * 2015-12-16 2021-04-22 Genentech, Inc. Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
ES2936827T3 (es) 2016-06-22 2023-03-22 Univ Vanderbilt Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3544961B1 (en) 2016-11-07 2021-08-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP7098167B2 (ja) 2016-11-07 2022-07-11 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
EP3558309B1 (en) 2016-11-07 2023-07-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
GB201702938D0 (en) 2017-02-23 2017-04-12 Univ Southampton Methods of generating and screening compartmentalised peptides libraries
CN111406058A (zh) 2017-12-05 2020-07-10 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
CN111801327B (zh) 2018-01-10 2024-02-09 里科瑞尔姆Ip控股有限责任公司 苯甲酰胺化合物
WO2022169882A1 (en) 2021-02-03 2022-08-11 Verge Analytics, Inc. Methods and treatment of viral infection caused by sars-cov-2
CN117751127A (zh) * 2021-08-20 2024-03-22 南京大美生物制药有限公司 一种五元含氮杂环并杂芳基类衍生物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU2001270260A1 (en) 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2004006846A2 (en) 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2557541C (en) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
AU2007242594A1 (en) * 2006-04-26 2007-11-01 F. Hoffmann-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
CA2650295C (en) * 2006-04-26 2015-12-29 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
ES2365258T3 (es) 2006-06-26 2011-09-27 Ucb Pharma S.A. Derivados de tiazol condensados como inhibidores de quinasa.
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
WO2008121257A1 (en) 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
WO2009094224A1 (en) * 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
JP2011529932A (ja) 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及び医薬としてのその使用
US20110257170A1 (en) 2008-10-03 2011-10-20 Merck Serono Sa 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2459543B1 (en) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
CA2771594C (en) 2009-08-20 2018-05-01 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
BR112014001768B1 (pt) 2011-07-27 2019-02-05 Astrazeneca Ab composto n-(2-{2-dimetilaminoetil-metilamino}-4-metóxi-5-{[4-(1-metilindol-3-il) pirimidin-2-il]amino}fenil) prop-2-enamida ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do dito composto
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
LT2994465T (lt) 2013-05-10 2018-10-10 Karus Therapeutics Limited Nauji histono deacetilazės inhibitoriai
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP3052494B1 (en) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
AU2010286168B2 (en) 2014-05-15
MX2012002059A (es) 2012-04-19
IL217903A (en) 2017-08-31
US9580442B2 (en) 2017-02-28
PL2467387T3 (pl) 2015-08-31
US9938290B2 (en) 2018-04-10
ZA201200910B (en) 2013-05-29
US10501478B2 (en) 2019-12-10
AU2010286168A1 (en) 2012-03-08
EP2467387A1 (en) 2012-06-27
EP2467387B1 (en) 2015-01-07
NZ597983A (en) 2014-05-30
ES2534326T3 (es) 2015-04-21
CN102498115A (zh) 2012-06-13
JP2013502404A (ja) 2013-01-24
US20180009826A1 (en) 2018-01-11
US20120178737A1 (en) 2012-07-12
CN102498115B (zh) 2016-12-07
IL217903A0 (en) 2012-03-29
US20190040079A1 (en) 2019-02-07
WO2011021038A1 (en) 2011-02-24
US20160108057A1 (en) 2016-04-21
BR112012003955A2 (pt) 2017-09-26
CA2771594A1 (en) 2011-02-24
JP5746172B2 (ja) 2015-07-08
CA2771594C (en) 2018-05-01
US9200007B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
IN2012DN01325A (enExample)
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
GEP201706728B (en) Noxious organism control agent
MY163498A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MY155517A (en) Heterocyclic derivatives
TN2011000400A1 (en) Inhibitors of beta-secretase
CA2875877C (en) Syk inhibitors
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
MY172924A (en) Neprilysin inhibitors
JO3465B1 (ar) مركب متغاير الحلقه واستخدامه
MD20140023A2 (ro) Derivaţi de pirolpirimidină şi purină
MX2010006421A (es) Compuestos organicos.
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
IN2014DN07509A (enExample)
NZ605558A (en) Benzamide derivatives and their use as hsp90 inhibitors
PH12012501643A1 (en) Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
PH12015502429A1 (en) Dicarboxylic acid compound
PH12013501840A1 (en) Nitrogen-containing saturated heterocyclic compound